Infinity (INFI) News a Positive for TG Therapeutics (TGTX) - Roth Capital

Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $25 price target on TG Therapeutics (NASDAQ: TGTX) after Infinity (NASDAQ: INFI) announced a collaboration with AbbVie (NASDAQ: ABBV) for the development and commercialization of INFI's PI3K-delta and gamma inhibitor duvelisib. INFI is entitled to a $275 million upfront payment, up to $530 million in additional milestones, shared U.S. profits, and tiered ex-U.S. royalties.

Pantginis said the Infinity deals is a positive for TG Therapeutics in terms of the untapped value of its differentiated PI3K inhibitor TGR-1202.

TG Therapeutics too would do in a partnership the analyst said. "Management has commented previously that the company would like to hold onto the drugs
for as long as possible, and possibly not partner at all. However, given the favorable terms that INFI secured in the deal with ABBV and given TGTX's
clinical data to date, we believe TGTX would have significant leverage if it chose to pursue a partnership."

The stock is also a Focus Pick at the firm.

Infinity Pharmaceuticals is is up 50% today on its news. Meanwhile, shares of TG Therapeutics are up 9.2% to $9.23.

For an analyst ratings summary and ratings history on TG Therapeutics click here. For more ratings news on TG Therapeutics click here.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Lockheed Martin (LMT) PT Raised to $487 at Deutsche Bank
• AGBA Group Holding (AGBA) selling off into close, down over 17%